摘要
目的探讨泌尿系结石伴尿路感染患者使用磷霉素氨丁三醇散(商品名:復安欣)、左氧氟沙星、环丙沙星治疗的临床疗效。方法选取90例泌尿系结石伴尿路感染患者,随机分为A组、B组、C组,各30例。A组患者给予復安欣治疗,B组患者给予左氧氟沙星治疗,C组患者给予环丙沙星治疗。比较三组临床治疗效果,治疗前后白细胞计数(WBC)和菌落数,不良反应发生情况,治疗前后炎症因子[C反应蛋白(CRP)、高迁移率族蛋白B1(HMGB1)、降钙素原(PCT)]水平。结果B组的临床治疗总有效率96.67%高于A组的70.00%和C组的76.67%,差异具有统计学意义(P<0.05)。治疗后,A组的WBC和菌落数分别为(7.84±0.66)个/HP、(83.27±4.33)CFU/ml,B组分别为(3.71±0.64)个/HP、(15.73±1.43)CFU/ml,C组分别为(5.64±0.63)个/HP、(52.14±1.43)CFU/ml;B组和C组的WBC和菌落数均明显低于A组,B组明显低于C组,差异具有统计学意义(P<0.05)。A组和B组不良反应总发生率分别为6.67%、3.33%,均明显低于C组的26.67%,差异具有统计学意义(P<0.05);B组不良反应总发生率略低于A组,但无显著性差异(P>0.05)。治疗后,A组的CRP、HMGB1、PCT水平分别为(20.73±1.72)mg/L、(81.72±6.42)ng/ml、(2.17±0.47)ng/ml,B组分别为(12.82±1.82)mg/L、(60.63±5.13)ng/ml、(0.52±0.41)ng/ml,C组分别为(18.72±1.78)mg/L、(72.73±5.63)ng/ml、(1.67±0.42)ng/ml;B组和C组的CRP、HMGB1、PCT水平明显低于A组,且B组低于C组,差异具有统计学意义(P<0.05)。结论对泌尿系结石伴尿路感染患者给予左氧氟沙星治疗具有较高的临床疗效,能够有效清除病原体,减轻炎症反应,且具有较高的治疗安全性。但是长期使用左氧氟沙星会给患者带来一定的耐药性,因此在临床中,应根据患者的实际情况给予最佳药物治疗。
Objective To explore the Comparison of the clinical efficacy of fosfomycin trometamol powder(trade name:Fosfomycin),levofloxacin and ciprofloxacin in patients with urinary stones and urinary tract infection.Methods A total of 90 patients with urinary stones and urinary tract infection were enrolled.They were randomly divided into group A,group B and group C,each consisting of 30 patients.Group A was treated with fosfomycin,group B was treated with levofloxacin,and group C was treated with ciprofloxacin.Comparison of clinical treatment effects,white blood cell count(WBC)and colony number before and after treatment,occurrence of adverse reactions,levels of inflammatory factors[C-reactive protein(CRP),high mobility group box 1(HMGB1),procalcitonin(PCT)]before and after treatment among the three groups.Results The total effective rate of group B was 96.67%,which was higher than that of group A(70.00%)and group C(76.67%),and the difference was statistically significant(P<0.05).After treatment,WBC count and colony number in group A were(7.84±0.66)/HP and(83.27±4.33)CFU/ml,those in group B were(3.71±0.64)/HP and(15.73±1.43)CFU/ml,and those in group C were(5.64±0.63)/HP and(52.14±1.43)CFU/ml.WBC count and colony number of groups B and C were significantly lower than those of group A,and group B was significantly lower than group C.The difference was statistically significant(P<0.05).The total incidence of adverse reactions in group A and group B were 6.67%and 3.33%,which was significantly lower than 26.67%in group C,and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in group B was slightly lower than that in group A,but therewas no significant difference(P>0.05).After treatment,the levels of CRP,HMGB1 and PCT in group A were(20.73±1.72)mg/L,(81.72±6.42)ng/ml and(2.17±0.47)ng/ml,those in group B were(12.82±1.82)mg/L,(60.63±5.13)ng/ml and(0.52±0.41)ng/ml,and those in group C were(18.72±1.78)mg/L,(72.73±5.63)ng/ml and(1.67±0.42)ng/ml.The levels of CRP,HMGB1 and PCT in group B and group C were significantly lower than those in group A,and group B was lower than group C.The difference was statistically significant(P<0.05).Conclusion Levofloxacin treatment has high clinical efficacy for patients with urinary stones and urinary tract infection,can effectively remove pathogens,reduce inflammation,and has high therapeutic safety.However,long-term use of levofloxacin will bring about certain drug resistance to patients,so in clinical practice,the best drug treatment should be given according to the actual situation of patients.
作者
朱训珂
ZHU Xun-ke(Inpatient Pharmacy,Jinxiang County People's Hospital,Jining 272200,China)
出处
《中国现代药物应用》
2025年第10期12-16,共5页
Chinese Journal of Modern Drug Application
关键词
泌尿系结石
尿路感染
磷霉素氨丁三醇散
左氧氟沙星
环丙沙星
不良反应
Urinary stones
Urinary tract infection
Fosfomycin trometamol powder
Levofloxacin
Ciprofloxacin
Adverse reactions
